Risk of lower sales due to product defects and competition
First written in FY2016. 7 of 12 entries say "Worsened", first in FY2024-Q1. Latest entry: 2026-07-30.
No other company in this theme has enough history to compare yet.
- 2026-07-30WorsenedEarnings
「Sales of ASULOCK, a treatment material for intertrochanteric femoral fractures, declined year on year due in part to intensifying competition.」
Intensifying competition was reflected in the first-quarter results as lower ASULOCK sales. - FY2026WorsenedAnnual report
「Sales of ASULOCK, a treatment material for intertrochanteric femoral fractures, declined slightly due to intensifying competition.」
The impact of intensified competition emerged in full-year results as a slight decline in ASULOCK sales. - 2026-05-08WorsenedEarnings
「Sales of ASULOCK, a treatment material for intertrochanteric femoral fractures, declined slightly due to intensifying competition.」
Intensifying competition was reflected in actual results as a decline in ASULOCK sales. - FY2026-H1WorsenedAnnual report
「In the osteosynthesis materials field, intensified competition limited growth in the Prima Hip Screw for femoral neck fracture treatment and ASULOCK for pertrochanteric femoral fracture treatment to single digits.」
Intensified competition was explicitly cited, and growth in the Prima Hip Screw and ASULOCK remained in the single digits. - FY2024WorsenedAnnual report
「Meanwhile, although sales of the Entrada Hip Stem and Alpine Hip Stem grew by double digits, sales across total hip arthroplasty (THA) declined because some customers switched from Taper Wedge stems, including the Ovation Tribute Stem, to competitors’ Triple Taper stems.」
Some customers continued to switch to competing products, and the impact of competitive risk emerged as a decline in total US hip replacement sales. - FY2024-Q3WorsenedAnnual report
「Meanwhile, although the market for hydroxyapatite (HA) coatings for hip products expanded and sales of the Entrada Hip Stem grew by double digits, sales across total hip arthroplasty (THA) declined because some customers switched from Taper Wedge stems, including the Ovation Tribute Stem, to competitors’ Triple Taper stems.」
In the US hip market, some customers switched to competitors’ Triple Taper products, and competitive risk newly emerged as a decline in total THA sales, including Taper Wedge products. - FY2024-Q2MitigatedAnnual report
「The number of cases won for the KMC Kyphoplasty System declined in the second half of the previous fiscal year as competitors entered the BKP (Balloon Kyphoplasty) market. However, after the start of the current fiscal year, the number of cases won turned upward as a result of measures implemented to capture growth opportunities from the expanding BKP market.」
The number of cases won for the KMC Kyphoplasty System, which had declined after competitors entered the BKP market, was reported to have begun increasing after measures were implemented to capture market expansion. - FY2024-Q1WorsenedAnnual report
「In the spinal fixation device field, sales of products including the Vusion Ti 3D Cage and Pisces Spinal System increased in Japan. Meanwhile, the number of cases won for the KMC Kyphoplasty System declined as competitors entered the BKP (Balloon Kyphoplasty) market. As a result, combined sales in Japan and the United States in this field were ¥821 million, down 0.7% year on year.」
The decline in cases won for the KMC Kyphoplasty System due to competitors entering the BKP market continued, and combined sales of spinal fixation devices in Japan and the United States fell 0.7% year on year. - FY2023-Q3MaterialisedAnnual report
「In the spinal fixation device field, growth in the KMC Kyphoplasty System slowed in Japan as new competitors entered the BKP (Balloon Kyphoplasty) market. However, sales of the Pisces Spinal System remained solid, and combined sales in Japan and the United States rose 2.8% year on year to ¥2,388 million.」
New competitors did enter the BKP market, and the impact has emerged as slower growth in the KMC Kyphoplasty System. - FY2020MitigatedAnnual report
「Unexpected defects and competition from other companies could reduce sales and affect profit or loss and financial position. To mitigate these risks, we have established a system for monthly reviews of defect occurrences and other companies’ sales trends.」
The risks of product defects and competition continue to be recognized, while a management process for monthly reviews of defect conditions and other companies’ sales trends has been specified. - FY2017RestatedAnnual report
「Unexpected defects and competition from other products in the same field may reduce sales and affect profit or loss and financial condition.」
The risk of lower sales due to product defects and competition continues to be disclosed. - FY2016First statedAnnual report
「Unexpected defects and competition from other products in the same field may reduce sales and affect profit or loss and financial condition.」
Product quality and the competitive environment are cited as factors behind the decline in sales.